Matching articles for "bebtelovimab"
COVID-19 Update: Bebtelovimab EUA Withdrawn (online only)
The Medical Letter on Drugs and Therapeutics • December 26, 2022; (Issue 1666)
The FDA has withdrawn its Emergency Use
Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
(LY-CoV1404 – Lilly) for treatment of COVID-19.
Bebtelovimab is not...
The FDA has withdrawn its Emergency Use
Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
(LY-CoV1404 – Lilly) for treatment of COVID-19.
Bebtelovimab is not expected to retain activity
against the Omicron variants BQ.1 and BQ.1.1, which
currently cause the majority of COVID-19 cases in all
regions of the US.
COVID-19 Update: Resistance to Bebtelovimab (online only)
The Medical Letter on Drugs and Therapeutics • November 28, 2022; (Issue 1664)
The FDA has warned that the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
is not expected to retain activity against the
Omicron variants BQ. and BQ.1.1.1 Bebtelovimab
(LY-CoV1404 –...
The FDA has warned that the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
is not expected to retain activity against the
Omicron variants BQ. and BQ.1.1.1 Bebtelovimab
(LY-CoV1404 – Lilly) is available under an FDA
Emergency Use Authorization (EUA) for IV treatment
of mild to moderate COVID-19 in high-risk patients
≥12 years old who weigh ≥40 kg for whom alternative
treatment options are unavailable or inappropriate.
The drug remains authorized for use in all regions
of the US.
COVID-19 Update: NIH Recommends Against Ivermectin
The Medical Letter on Drugs and Therapeutics • June 13, 2022; (Issue 1652)
On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled...
On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled trials of ivermectin have produced negative results and because alternative drugs that have been shown to be effective for treatment of COVID-19 are available.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • April 18, 2022; (Issue 1648)
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use as a second
booster dose...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use as a second
booster dose ≥4 months after a first booster dose in
adults ≥50 years old and in persons aged ≥12 years
(Pfizer) or ≥18 years (Moderna) who have undergone
solid organ transplantation or have a condition that
compromises the immune system to a similar extent.
An EUA for Bebtelovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • March 21, 2022; (Issue 1646)
The investigational monoclonal antibody
bebtelovimab (LY-CoV1404 – Lilly) has been granted
an FDA Emergency Use Authorization (EUA) for IV
treatment of mild to moderate COVID-19 in patients
≥12 years...
The investigational monoclonal antibody
bebtelovimab (LY-CoV1404 – Lilly) has been granted
an FDA Emergency Use Authorization (EUA) for IV
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death, and for whom alternative
treatment options are unavailable or inappropriate.
Bebtelovimab is active against the Omicron variant of
SARS-CoV-2; sotrovimab (VIR-7831) is the only other
monoclonal antibody currently available for treatment
of COVID-19 that is active against Omicron.